In 2019, sales of insulins at the ex-manufacturer price level exceeded $11 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2019-2029 forecast period, the originator insulins manufactured by Eli Lilly, Novo Nordisk, and Sanofi will face increasing competition from insulin biosimilars / follow-on insulins, eroding both patient share and drug prices. We present our forecasts for key reference brand insulins and their biosimilars / follow-on insulins by therapeutic area, molecule, and country / region.

Table of contents

  • Biosimilars - Market Events And Forecast - Endocrinology
    • Market Forecast in the Major Pharmaceutical Markets
      • Major-Market Forecast: Endocrinology Biologics (Insulin Analogues)
      • Terminology
      • Overarching Forecast Assumptions
        • Overview of Insulin Brands in Forecast
          • Overview of Approved Insulins
          • Biosimilar Entry Assumptions for Approved Insulins
        • Overview of Insulin Biosimilar Assumptions
        • Drug-Specific Forecast Assumptions
          • Lantus
            • Outlook for Lantus
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturing Price Assumptions
            • Lantus Sales Forecast in the United States: 2019-2029
            • Lantus Sales Forecast in the EU5: 2019-2029
            • Lantus Sales Forecast in Japan: 2019-2029
          • Levemir
            • Outlook for Levemir
            • First Major-Market Biosimilar Entrants
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturing Price Assumptions
            • Levemir Sales Forecast in the United States: 2019-2029
            • Levemir Sales Forecast in the EU5: 2019-2029
            • Levemir Sales Forecast in Japan: 2019-2029
          • Humalog / Humalog Mix
            • Outlook for Humalog / Humalog Mix
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturing Price Assumptions
            • Humalog / Humalog Mix Sales Forecast in the United States: 2019-2029
            • Humalog / Humalog Mix Sales Forecast in the EU5: 2019-2029
            • Humalog / Humalog Mix Sales Forecast in Japan: 2019-2029
          • NovoLog / NovoRapid and NovoMix
            • Outlook for NovoLog / NovoRapid and NovoMix
            • First Major-Market Biosimilar Entrants NovoLog / NovoRapid
            • First Major-Market Biosimilar Entrants NovoMix
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturing Price Assumptions
            • NovoLog / NovoRapid Sales Forecast in the United States: 2019-2029
            • NovoLog / NovoRapid Sales Forecast in the EU5: 2019-2029
            • NovoLog / NovoRapid Sales Forecast in Japan: 2019-2029
            • NovoMix Sales Forecast in the United States: 2019-2029
            • NovoMix Sales Forecast in the EU5: 2019-2029
            • NovoMix Sales Forecast in Japan: 2019-2029

      Author(s): Hamzah Aideed, M.Sc.; Yashu Malhotra

      Hamzah Aideed, M.Sc., is a principal analyst on the Biosimilars team at DRG, part of Clarivate. He conducts primary and secondary market research to provide in-depth analysis and insight into the biopharmaceutical industry. Prior to joining DRG, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.

      Yashu Malhotra, M.Sc., is an associate analyst on the Biosimilars and Onkos teams at DRG, part of Clarivate. Prior to joining DRG, she was a senior analyst in the life sciences at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master’s degree in pharmacy (quality assurance) from India’s Delhi Institute of Pharmaceutical Sciences and Research.